Sabina Murgioni

7PUBLICATIONS
70CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 13, 2026
Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment.

Roberto Moretto, Vittorio Studiale, Seung Won Hyun

|Jan 08, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti

|Nov 07, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.

Roberto Moretto, Daniele Rossini, Sabina Murgioni

|Jul 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Marinde J G Bond, Maarten van Smeden, Koen Degeling

|Apr 06, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.

Carlotta Antoniotti, Alessandra Boccaccino, Robert Seitz

|Jun 06, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.

Daniele Rossini, Carlotta Antoniotti, Sara Lonardi

Pageof 2

Frequent Collaborators

7 joint publications

Chiara Cremolini

6 joint publications

Filippo Pietrantonio

5 joint publications

Sara Lonardi

4 joint publications

Veronica Conca